Atenolol in Migraine Prophylaxis a Double-blind Cross-over Multicentre Study
| Autor: | Tommy Jäverfalk, Anders Raak, Valur Johannsson, Margareta Troein, Göran Almkvist, CarI-Lennart Gustafsson, Björn Tilling, Tommy Widelius, Lars R. Nilsson, Peter Hellman, Jan-Åke Åkesson, Bengt Olerud, Gun Sandahl |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Adult
Male Migraine Disorders medicine.medical_treatment Placebo Migraine prophylaxis Double blind Double-Blind Method Humans Medicine Cross over Clinical Trials as Topic Chemotherapy business.industry Middle Aged Atenolol medicine.disease Treatment period Neurology Migraine Anesthesia Female Neurology (clinical) business circulatory and respiratory physiology medicine.drug |
| Zdroj: | Headache: The Journal of Head and Face Pain. 27:372-374 |
| ISSN: | 1526-4610 0017-8748 |
| Popis: | SYNOPSIS The prophylactic anti-migraine effect of atenolol was compared to placebo in a multicentre study on 63 patients with classical and/or common migraine. The study design was double-blind cross-over and patients were given atenolol 100 mg o.d. or matching placebo during a study treatment period of 24 weeks. The effect of atenolol was significantly better than that of placebo: integrated headache values were reduced in 70% of the patients (p = 0.004) and the proportion of days with headache was reduced in 59% of the patients (p = 0.010). Few side effects were reported with both atenolol and placebo. This study shows atenolol to be safe and effective in the prophylactic treatment of migraine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text